Edition:
United Kingdom

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

3,823JPY
7:00am BST
Change (% chg)

¥0 (+0.00%)
Prev Close
¥3,823
Open
¥3,850
Day's High
¥3,854
Day's Low
¥3,806
Volume
3,045,600
Avg. Vol
6,846,255
52-wk High
¥4,943
52-wk Low
¥3,498

Select another date:

Wed, Jun 5 2019

Photo

Takeda scraps late-stage amyloidosis study

Takeda Pharmaceutical Co Ltd said on Wednesday it would discontinue a late-stage study testing its experimental treatment for amyloidosis, as it did not meet the first of two main goals.

Takeda scraps late-stage amyloidosis study

June 5 Takeda Pharmaceutical Co Ltd said on Wednesday it would discontinue a late-stage study testing its experimental treatment for amyloidosis, as it did not meet the first of two main goals.

Japan's Takeda expects binding offers for Latam business by end of May: sources

SAO PAULO Japan's Takeda Pharmaceutical Co expects to receive binding offers for its Latin American business by the end of May, three sources with knowledge of the matter said.

Japan's Takeda expects binding offers for Latam business by end of May -sources

SAO PAULO, May 16 Japan's Takeda Pharmaceutical Co expects to receive binding offers for its Latin American business by the end of May, three sources with knowledge of the matter said.

Japan's Takeda forecasts surprise annual loss on Shire-related costs

TOKYO Takeda Pharmaceutical Co forecast an unexpected operating loss for the current year due to costs associated with the $59 billion purchase of Shire Plc, providing the first set of financial results of the combined firm.

UPDATE 2-Japan's Takeda forecasts surprise annual loss on Shire-related costs

* 193 bln Y op loss forecast this yr vs 227.5 bln profit view of analysts

Japan's Takeda forecasts 193 billion yen annual operating loss on Shire deal

TOKYO Takeda Pharmaceutical Co forecast on Tuesday it would have an operating loss in the current financial year, as it books costs associated with the multibillion-dollar Shire deal.

Japan's Takeda expects annual loss on Shire deal

TOKYO, May 14 Takeda Pharmaceutical Co forecast on Tuesday it would have an operating loss in the current financial year, as it books costs associated with the multibillion-dollar Shire deal.

Novartis buys dry eye drug from Takeda for up to $5.3 billion

TOKYO/ZURICH Novartis is buying dry-eye drug Xiidra from Takeda Pharmaceutical Co for up to $5.3 billion as the Swiss drugmaker refreshes its ophthalmic medicines portfolio with a potential blockbuster.

Novartis buys dry eye drug from Takeda for up to $5.3 billion

TOKYO/ZURICH Novartis is buying dry-eye drug Xiidra from Takeda Pharmaceutical Co for up to $5.3 billion (£4.08 billion) as the Swiss drugmaker refreshes its ophthalmic medicines portfolio with a potential blockbuster.

Select another date: